Reference : Replacement of Glycoprotein B in Alcelaphine Herpesvirus 1 by Its Ovine Herpesvirus 2...
Scientific journals : Article
Life sciences : Veterinary medicine & animal health
http://hdl.handle.net/2268/201280
Replacement of Glycoprotein B in Alcelaphine Herpesvirus 1 by Its Ovine Herpesvirus 2 Homolog : Implications in Vaccine Development for Sheep-Associated Malignant Catarrhal Fever.
English
Cunha, Cristina W. [> >]
Taus, Naomi S. [> >]
Dewals, Benjamin G mailto [Université de Liège > > Immunologie et vaccinologie >]
Vanderplasschen, Alain mailto [Université de Liège > > Immunologie et vaccinologie >]
Knowles, Donald P. [> >]
Li, Hong [> >]
3-Aug-2016
mSphere
1
4
e00108-16
Yes
International
2379-5042
2379-5042
United States
[en] Chimeric virus ; alcelaphine herpesvirus 1 ; malignant catarrhal fever ; ovine herpesvirus 2 ; vaccine
[en] Vaccine development is a top priority in malignant catarrhal fever (MCF) research. In the case of sheep-associated MCF (SA-MCF) caused by ovine herpesvirus 2 (OvHV-2), progress toward this objective has been hindered by the absence of methods to attenuate or modify the virus, since it cannot be propagated in vitro. As an alternative for vaccine development, in this study, we tested the hypothesis that one of the SA-MCF vaccine candidate targets, OvHV-2 glycoprotein B (gB), could be expressed by a nonpathogenic alcelaphine herpesvirus 1 (AlHV-1) and then evaluated the potential of the AlHV-1/OvHV-2 chimera to be used as a vaccine and a diagnostic tool. The construction and characterization of an AlHV-1/OvHV-2 chimeric virus that is nonpathogenic and expresses an OvHV-2 vaccine target are significant steps toward the development of an SA-MCF vaccine and also provide a valuable means to study OvHV-2 biology.
http://hdl.handle.net/2268/201280
10.1128/mSphere.00108-16

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Cunha,16.pdfPublisher postprint1.14 MBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.